DERM Stock Overview
Focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 4/6 |
Past Performance | 2/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Journey Medical Corporation Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$6.53 |
52 Week High | US$8.11 |
52 Week Low | US$2.65 |
Beta | 0.93 |
11 Month Change | 39.53% |
3 Month Change | 14.76% |
1 Year Change | 125.95% |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -31.26% |
Recent News & Updates
Journey Medical Corporation (NASDAQ:DERM) Shares Fly 31% But Investors Aren't Buying For Growth
Oct 03Here's Why Journey Medical (NASDAQ:DERM) Has A Meaningful Debt Burden
Sep 14Recent updates
Journey Medical Corporation (NASDAQ:DERM) Shares Fly 31% But Investors Aren't Buying For Growth
Oct 03Here's Why Journey Medical (NASDAQ:DERM) Has A Meaningful Debt Burden
Sep 14Does Journey Medical (NASDAQ:DERM) Have A Healthy Balance Sheet?
May 06Journey Medical Corporation (NASDAQ:DERM) Not Doing Enough For Some Investors As Its Shares Slump 31%
Mar 11Journey Medical Corporation's (NASDAQ:DERM) 33% Dip In Price Shows Sentiment Is Matching Revenues
Jan 18Journey Medical Corporation's (NASDAQ:DERM) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Nov 10US$12.00: That's What Analysts Think Journey Medical Corporation (NASDAQ:DERM) Is Worth After Its Latest Results
May 12Shareholder Returns
DERM | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | 14.2% | -0.09% | 0.4% |
1Y | 126.0% | 19.0% | 32.6% |
Return vs Industry: DERM exceeded the US Pharmaceuticals industry which returned 19% over the past year.
Return vs Market: DERM exceeded the US Market which returned 32.6% over the past year.
Price Volatility
DERM volatility | |
---|---|
DERM Average Weekly Movement | 9.5% |
Pharmaceuticals Industry Average Movement | 9.5% |
Market Average Movement | 6.4% |
10% most volatile stocks in US Market | 15.0% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: DERM has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: DERM's weekly volatility (9%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2014 | 41 | Claude Maraoui | journeymedicalcorp.com |
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company’s marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis.
Journey Medical Corporation Fundamentals Summary
DERM fundamental statistics | |
---|---|
Market cap | US$135.35m |
Earnings (TTM) | US$843.00k |
Revenue (TTM) | US$77.68m |
160.6x
P/E Ratio1.7x
P/S RatioIs DERM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
DERM income statement (TTM) | |
---|---|
Revenue | US$77.68m |
Cost of Revenue | US$25.80m |
Gross Profit | US$51.88m |
Other Expenses | US$51.04m |
Earnings | US$843.00k |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 0.041 |
Gross Margin | 66.79% |
Net Profit Margin | 1.09% |
Debt/Equity Ratio | 201.4% |
How did DERM perform over the long term?
See historical performance and comparison